BBOT
insider transactionsBridgeBio Oncology Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
31.7K sh
Own New
-
Grant·A
Director
$0
31.7K sh
Own New
-
Grant·A
Director
$0
7.3K sh
Own New
-
Grant·A
Director
$0
31.7K sh
Own New
-
Grant·A
Director, 10% Owner
$0
31.7K sh
Own New
-
Grant·A
Director
$0
31.7K sh
Own New
-
Grant·A
Director
$0
31.7K sh
Own New
-
Grant·A
Director
$0
12.3K sh
Own New
-
Grant·A
Director
$0
3.8K sh
Own +50%
-
Grant·A
COO & Principal Financial Ofcr
$0
758.2K sh
Own New
-
Grant·A
Pedro Beltran KEY
President and CEO
$0
1.1M sh
Own New
-
Grant·A
Director
$0
7.1K sh
Own New
-
Grant·A
Director
$0
13.9K sh
Own +55%
-
Other·F
Other
$4.7K
524 sh · $9.03
Own -2%
-
Other·F
Chief Med & Dev Officer
$9.5K
1.0K sh · $9.03
Own -2%
-
Other·F
Pedro Beltran KEY
President and CEO
$9.5K
1.0K sh · $9.03
Own -2%
-
Grant·A
Director
$0
63.4K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 16, 2026 | Praveen P. Tipirneni | Grant A | 31.7K | $0 |
| Jun 16, 2026 | Frank Mccormick | Grant A | 31.7K | $0 |
| Jun 16, 2026 | Peter F Lebowitz | Grant A | 7.3K | $0 |
| Jun 16, 2026 | Raymond J. Kelleher | Grant A | 31.7K | $0 |
| Jun 16, 2026 | Bihua Chen | Grant A | 31.7K | $0 |
| Jun 16, 2026 | Neil Kumar | Grant A | 31.7K | $0 |
| Jun 16, 2026 | Jake Bauer | Grant A | 31.7K | $0 |
| May 19, 2026 | Yong Ben | Grant A | 12.3K | $0 |
| May 19, 2026 | Yong Ben | Grant A | 3.8K | $0 |
| May 10, 2026 | Idan Elmelech | Grant A | 758.2K | $0 |
| May 10, 2026 | Pedro Beltran KEY | Grant A | 1.1M | $0 |
| Apr 7, 2026 | Jake Bauer | Grant A | 7.1K | $0 |
| Apr 7, 2026 | Jake Bauer | Grant A | 13.9K | $0 |
| Apr 1, 2026 | Uneek Mehra | Other F | 524 | $4.7K |
| Apr 1, 2026 | Yong Ben | Other F | 1.0K | $9.5K |
| Apr 1, 2026 | Pedro Beltran KEY | Other F | 1.0K | $9.5K |
| Mar 24, 2026 | Peter F Lebowitz | Grant A | 63.4K | $0 |
About BBOT insider trading
This page tracks insider transactions for BridgeBio Oncology Therapeutics, Inc. (BBOT) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.